Physicians' Academy for Cardiovascular Education

Stroke

A positive view on a negative trial with DOAC after TAVR

3' education - Apr. 19, 2022 - Megan Coylewright, MD

Implementation of salt substitution strategies

3' education - Sep. 21, 2021 - Prof. Barbara Casadei, MD

Switching to a salt substitute reduces risk of stroke, CV events and death

5' education - Aug. 31, 2021 - Prof. Bruce Neal, MD, PhD

Head-to-head comparison of risk scores for ischemic stroke in patients with AF and CKD

5' education - June 14, 2001 - Ype de Jong, MD

Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients

5' education - Nov. 23, 2020 - Prof. Deepak Bhatt, MD

Updates in the 2020 AF guidelines

3' education - Sep. 2, 2020 - Prof. Isabelle van Gelder, MD

Early rhythm control in AF patients improves outcomes

3' education - Aug. 29, 2020 - Prof. Paulus Kirchhof, MD

Challenges in prescribing DOACs for stroke prevention in AF

5' education - Mar. 2, 2020 - Prof. Freek Verheugt and John Eikelboom

Long-term treatment with dual antiplatelet therapy in patients with diabetes and stable CAD

3' education - Sep. 9, 2019 - Prof. Ph. Gabriel Steg

Long term benefits of antihypertensive and cholesterol-lowering treatment in hypertension

10' education - Nov. 20, 2018 - Dr. Ajay Gupta - London, UK

Higher healthy diet score is associated with a lower risk of mortality and CV events across the globe

3' education - Aug. 28, 2018 - Dr. Andrew Mente, Hamilton, ONT, Canada

Machine learning program predicts that drinking more coffee lowers risk of CVD and stroke

3' education - Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Laura M Stevens - Aurora, CO, USA
##SCROLLER_ITEMS_FULL_TITLE##

Stroke reduction with PPAR-Y antagonist pioglitazone

3' education - May 6, 2016 - Dubai, UAE - Dr Robert J Chilton
##SCROLLER_ITEMS_FULL_TITLE##

PEGASUS: Clinical judgement needed

3' education - Mar. 16, 2015 - ACC 2015, San Diego - Valentin Fuster, MD Mount Sinai Hospital, New York,NY
##SCROLLER_ITEMS_FULL_TITLE##

Translating new clinical trial data of DOACs for stroke prevention into clinical practice

3' education - Mar. 30, 2014 - VBWG at ACC - Michael Ezekowitz MD, PhD
##SCROLLER_ITEMS_FULL_TITLE##

Neurological complications in diabetes

3' education - Apr. 23, 2014 - CDMC Almaty - Boris Mankovsky

Absolute effects of PCSK9i and ezetimibe across different CVD risk groups

Literature - July 18, 2022 - Khan SU, et al. - BMJ. 2022

A network meta-analysis shows both PCSK9i and ezetimibe may reduce non-fatal MI and stroke in adults on maximum statin therapy or with statin intolerance who are at very high or high CVD risk but not in those at moderate or low risk.

Fewer first strokes in T2DM patients after GLP-1RA treatment

Literature - May 31, 2022 - Strain WD et al. - Stroke. 2022

Semaglutide reduces the risk of any first stroke in T2DM patients at high CVD risk, as revealed by an exploratory post-hoc analysis of the SUSTAIN 6 and PIONEER 6 trial . History of stroke had no influence on this effect.

Very old AF patients in Japan benefit from very low-dose DOAC

Literature - May 31, 2022 - Kuroda M, et al. - JAMA Cardiol. 2022

In Japanese AF patients aged ≥80 years with high bleeding risk, edoxaban 15 mg reduced the incidence of stroke or systemic embolism across three age strata (80–84 years, 85–89 years, and ≥90 years), with no significant safety risk. Still, these results may not apply to other ethnic groups.

A positive view on a negative trial with DOAC after TAVR

3' education - Apr. 19, 2022 - Megan Coylewright, MD
Megan Coylewright gives her view on the results of the ADAPT-TAVR trial which investigated whether edoxaban, compared to DAPT can reduce leaflet thrombosis, cerebral thromboembolism and neurological/neurocognitive dysfunction after TAVR.

ACC 2022 Megan Coylewright gives her view on the results of the ADAPT-TAVR trial which investigated whether edoxaban, compared to DAPT can reduce leaflet thrombosis, cerebral thromboembolism and neurological/neurocognitive dysfunction after TAVR.

Factor XIa inhibitor lowers bleeding rate compared with NOAC in AF patients

News - Apr. 11, 2022

ACC 2022 The factor XIa inhibitor asundexian lowers bleeding rate compared with apixaban in patients with AF in the phase 2 PACIFIC-AF trial.

Effectiveness and safety of anticoagulant therapy in patients with AF at low stroke risk

Literature - Mar. 21, 2022 - Komen JJ et al. - Eur Heart J. 2022

The results of an observational study suggest that treatment with DOAC may be associated with a positive net clinical benefit compared with VKA and no anticoagulation treatment in patients with AF at low stroke risk.

Proteomic risk model superior to clinical risk model in predicting recurrent ASCVD events

Literature - Mar. 9, 2022 - Nurmohamed NS et al. - Eur Heart J. 2022

This study investigated the predictive value of a targeted plasma proteomics approach, analyzed with machine learning techniques in a secondary prevention setting.

PD-L2 as potential novel biomarker of arterial thromboembolic risk in AF

Literature - Feb. 16, 2022 - Berg DD, et al. - JACC 2021

A nested case-control study with a proteomic approach identified programmed cell death 1 ligand 2 (PD-L2) as a potential novel biomarker of ischemic stroke/systemic embolic event risk in patients with AF who were enrolled in the ENGAGE AF-TIMI 48 trial.

Improved outcomes with DOAC in AF and ACS and/or PCI independent of bleeding and stroke risk

Literature - Feb. 10, 2022 - Harskamp RE, et al. - J Am Coll Cardiol 2022

No significant interaction was found on treatment effect of apixaban vs. VKA or aspirin vs. placebo across HAS-BLED or CHA2DS-VASc categories in patients with AF in the first 6 months following an ACS and/or PCI, in a post hoc analysis of the AUGUSTUS trial.

Comparing P2Y12 inhibitors in patients with stroke who are CYP2C19 LOF carriers

Literature - Dec. 20, 2021 - Wang Y, et al. - N Engl J Med 2021

In the CHANCE-2 trial, treatment with ticagrelor and aspirin reduces recurrent stroke at 90 days compared to use of clopidogrel and aspirin in Chinese patients with minor ischemic stroke or TIA who are carriers of CYP2C19 LOF alleles. Risk of severe or moderate bleeding was…

Differential associations of eGFR and UACR with CVD subtypes in patients with diabetes

News - Sep. 29, 2021
In patients with diabetes, included in the Hoorn Diabetes Care System cohort, measures of kidney disease, eGFR and UACR, were differentially associated with subtypes of CVD.

EASD 2021 In patients with diabetes, included in the Hoorn Diabetes Care System cohort, measures of kidney disease, eGFR and UACR, were differentially associated with subtypes of CVD.

Implementation of salt substitution strategies

3' education - Sep. 21, 2021 - Prof. Barbara Casadei, MD
Prof. Casadei gives her opinion about what we should do with the evidence from the Salt Substitute and Stroke Study (SSaSS), which showed that switching to a salt substitute reduces the risk of stroke, CV events and death.

ESC 2021 Prof. Casadei gives her opinion about what we should do with the evidence from the Salt Substitute and Stroke Study (SSaSS), which showed that switching to a salt substitute reduces the risk of stroke, CV events and death.